Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition.
Favourable long-term effects of a cardiovascular prevention program in primary health care in Sweden in men, and women on first cardiovascular events, cardiovascular mortality, and all-cause mortality